<p>根據 Invesco Ltd.最近向 SEC 提交的 13F 文件，該公司在 2023 年第四季度減少了對諾和諾德公司（NYSE:NVO - 免費報告）32.9% 的持股。該公司在季度內出售了 171,244 股後，持有 349,208 股諾和諾德公司的股票。在最近的報告期結束時，Invesco Ltd.在諾和諾德公司的持股價值為 30,039,000 美元。</p>
<p>獲取 <strong>諾和諾德公司</strong> 的提醒：</p>
<ul>
<li>Viking Therapeutics 股票上漲但難以維持漲幅</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也增加或減少了對 NVO 的持股。GQG Partners LLC 在第四季度將其在諾和諾德公司的持股增加了 74.7%。GQG Partners LLC 現在擁有 12,994,533 股諾和諾德公司的股票，價值 1,117,790,000 美元，此前在上個季度又收購了 5,556,460 股。Raymond James Financial Inc.在第四季度購買了諾和諾德公司的新股份，價值約 404,910,000 美元。Loomis Sayles &amp; Co. L P 在第四季度將其在諾和諾德公司的持股增加了 34.2%。Loomis Sayles &amp; Co. L P 現在擁有 11,571,686 股諾和諾德公司的股票，價值 995,397,000 美元，此前在上個季度又購買了 2,947,771 股。Clearbridge Investments LLC 在第四季度將其在諾和諾德公司的持股增加了 59.8%。Clearbridge Investments LLC 現在擁有 4,283,317 股諾和諾德公司的股票，價值 368,451,000 美元，此前在上個季度又購買了 1,602,549 股。最後，Sustainable Growth Advisers LP 在第四季度將其在諾和諾德公司的持股增加了 23.6%。Sustainable Growth Advisers LP 現在擁有 5,340,803 股諾和諾德公司的股票，價值 459,416,000 美元，此前在上個季度又購買了 1,021,498 股。對沖基金和其他機構投資者持有該公司 11.54% 的股票。</p>
<h2>諾和諾德公司價格表現</h2>
<p>週五，NYSE NVO 的開盤價為 57.99 美元。該股票的 50 日簡單移動平均線為 76.03 美元，200 日簡單移動平均線為 92.13 美元。諾和諾德公司的 12 個月低點為 57.28 美元，12 個月高點為 148.15 美元。該股票的市值為 2602.3 億美元，市盈率為 17.63，市盈增長比率為 0.90，貝塔值為 0.61。該公司的債務與股本比率為 0.62，速動比率為 0.55，流動比率為 0.74。</p>
<ul>
<li>目前哪個醫療保健股票是最佳買入？</li>
</ul>
<p>諾和諾德公司（NYSE:NVO - 獲取免費報告）最近在 2 月 5 日發佈了季度財報。該公司報告季度每股收益為 0.91 美元，超出分析師一致預期的 0.88 美元，超出幅度為 0.03 美元。諾和諾德公司的股本回報率為 84.68%，淨利潤率為 34.81%。研究分析師預計諾和諾德公司今年的每股收益將達到 3.84 美元。</p>
<h2>諾和諾德公司增加股息</h2>
<p>該公司最近還披露了一項半年度股息，該股息於 4 月 8 日（星期二）支付。3 月 31 日（星期一）登記在冊的股東獲得每股 0.7874 美元的股息。這比諾和諾德公司之前的半年度股息 0.51 美元有所增加。除息日期為 3 月 31 日（星期一）。這代表了 1.2% 的股息收益率。諾和諾德公司的派息比率目前為 49.54%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
<p>NVO 已成為多份分析師報告的主題。Kepler Capital Markets 在 3 月 13 日（星期四）的研究報告中將諾和諾德公司的股票評級從 “持有” 上調至 “買入”。StockNews.com 在週二的研究報告中將諾和諾德公司的股票評級從 “強力買入” 下調至 “買入”。Stifel Nicolaus 在 3 月 3 日（星期一）的研究報告中將諾和諾德公司的股票評級從 “買入” 下調至 “持有”。BMO Capital Markets 在週四的研究報告中重申了 “市場表現” 評級，並對諾和諾德公司的股票設定了 64.00 美元的目標價（之前為 105.00 美元）。最後，瑞銀集團在 1 月 8 日（星期三）的報告中將諾和諾德公司的評級從 “賣出” 上調至 “買入”。一位投資分析師對該股票給予了 “賣出” 評級，四位給予了 “持有” 評級，六位給予了 “買入” 評級。根據 MarketBeat.com，諾和諾德公司目前的平均評級為 “持有”，平均目標價為 135.00 美元。</p>
<p><strong>查看我們對 NVO 的最新分析</strong></p>
<h2>諾和諾德公司公司簡介</h2>
<p>（免費報告）</p>
<p>諾和諾德公司及其子公司從事藥品的研究與開發、生產和分銷業務，覆蓋歐洲、中東、非洲、中國大陸、香港、台灣、北美及國際市場。它分為兩個部門，分別是糖尿病與肥胖護理和罕見疾病。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票超過諾和諾德公司</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>關税豁免為台灣半導體的反彈鋪平道路</li>
<li>如何投資最佳的加拿大股票</li>
<li>緩解關税：三隻股票從美元走弱中獲益</li>
<li>稀釋每股收益（Diluted EPS）是什麼？</li>
<li>博通與蘋果的關係：人工智能機會與關税風險的交匯</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在諾和諾德公司嗎？</h2>
<p>在考慮諾和諾德公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而諾和諾德公司並不在名單上。</p>
<p>雖然諾和諾德公司目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

景順投資管理

諾和諾德公司

<p>景順投資管理（Invesco Ltd.）在第四季度將其在諾和諾德公司（Novo Nordisk A/S，NYSE:NVO）的持股比例減少了 32.9%，在出售 171,244 股後，持有 349,208 股。其他機構投資者也調整了他們的持股，GQG Partners LLC 將其持股比例增加了 74.7%。諾和諾德的股票開盤價為 57.99 美元，市值為 2602.3 億美元，市盈率為 17.63。該公司最近報告的每股收益（EPS）為 0.91 美元，超出預期，並將其半年度股息提高至每股 0.7874 美元</p>

<p>Invesco Ltd. lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 32.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 349,208 shares of the company's stock after selling 171,244 shares during the quarter. Invesco Ltd.'s holdings in Novo Nordisk A/S were worth $30,039,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據 Invesco Ltd.最近向 SEC 提交的 13F 文件，該公司在 2023 年第四季度減少了對諾和諾德公司（NYSE:NVO - 免費報告）32.9% 的持股。該公司在季度內出售了 171,244 股後，持有 349,208 股諾和諾德公司的股票。在最近的報告期結束時，Invesco Ltd.在諾和諾德公司的持股價值為 30,039,000 美元。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>諾和諾德公司</strong> 的提醒：</p>
</div><ul>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 股票上漲但難以維持漲幅</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. GQG Partners LLC raised its holdings in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $404,910,000. Loomis Sayles &amp; Co. L P lifted its holdings in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles &amp; Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after buying an additional 1,602,549 shares in the last quarter. Finally, Sustainable Growth Advisers LP increased its holdings in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after buying an additional 1,021,498 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也增加或減少了對 NVO 的持股。GQG Partners LLC 在第四季度將其在諾和諾德公司的持股增加了 74.7%。GQG Partners LLC 現在擁有 12,994,533 股諾和諾德公司的股票，價值 1,117,790,000 美元，此前在上個季度又收購了 5,556,460 股。Raymond James Financial Inc.在第四季度購買了諾和諾德公司的新股份，價值約 404,910,000 美元。Loomis Sayles &amp; Co. L P 在第四季度將其在諾和諾德公司的持股增加了 34.2%。Loomis Sayles &amp; Co. L P 現在擁有 11,571,686 股諾和諾德公司的股票，價值 995,397,000 美元，此前在上個季度又購買了 2,947,771 股。Clearbridge Investments LLC 在第四季度將其在諾和諾德公司的持股增加了 59.8%。Clearbridge Investments LLC 現在擁有 4,283,317 股諾和諾德公司的股票，價值 368,451,000 美元，此前在上個季度又購買了 1,602,549 股。最後，Sustainable Growth Advisers LP 在第四季度將其在諾和諾德公司的持股增加了 23.6%。Sustainable Growth Advisers LP 現在擁有 5,340,803 股諾和諾德公司的股票，價值 459,416,000 美元，此前在上個季度又購買了 1,021,498 股。對沖基金和其他機構投資者持有該公司 11.54% 的股票。</p>
</div><h2>Novo Nordisk A/S Price Performance</h2>
<div class="lb-trans"><h2>諾和諾德公司價格表現</h2>
</div><p>NYSE NVO opened at $57.99 on Friday. The stock has a 50-day simple moving average of $76.03 and a 200 day simple moving average of $92.13. Novo Nordisk A/S has a twelve month low of $57.28 and a twelve month high of $148.15. The stock has a market capitalization of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.</p>
<div class="lb-trans"><p>週五，NYSE NVO 的開盤價為 57.99 美元。該股票的 50 日簡單移動平均線為 76.03 美元，200 日簡單移動平均線為 92.13 美元。諾和諾德公司的 12 個月低點為 57.28 美元，12 個月高點為 148.15 美元。該股票的市值為 2602.3 億美元，市盈率為 17.63，市盈增長比率為 0.90，貝塔值為 0.61。該公司的債務與股本比率為 0.62，速動比率為 0.55，流動比率為 0.74。</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪個醫療保健股票是最佳買入？</li>
</ul>
</div><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.</p>
<div class="lb-trans"><p>諾和諾德公司（NYSE:NVO - 獲取免費報告）最近在 2 月 5 日發佈了季度財報。該公司報告季度每股收益為 0.91 美元，超出分析師一致預期的 0.88 美元，超出幅度為 0.03 美元。諾和諾德公司的股本回報率為 84.68%，淨利潤率為 34.81%。研究分析師預計諾和諾德公司今年的每股收益將達到 3.84 美元。</p>
</div><h2>Novo Nordisk A/S Increases Dividend</h2>
<div class="lb-trans"><h2>諾和諾德公司增加股息</h2>
</div><p>The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's payout ratio is presently 49.54%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項半年度股息，該股息於 4 月 8 日（星期二）支付。3 月 31 日（星期一）登記在冊的股東獲得每股 0.7874 美元的股息。這比諾和諾德公司之前的半年度股息 0.51 美元有所增加。除息日期為 3 月 31 日（星期一）。這代表了 1.2% 的股息收益率。諾和諾德公司的派息比率目前為 49.54%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
</div><p>NVO has been the subject of a number of analyst reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Thursday, March 13th. StockNews.com lowered shares of Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, March 3rd. BMO Capital Markets reaffirmed a &#34;market perform&#34; rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday. Finally, UBS Group raised Novo Nordisk A/S from a &#34;sell&#34; rating to a &#34;buy&#34; rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of &#34;Hold&#34; and an average price target of $135.00.</p>
<div class="lb-trans"><p>NVO 已成為多份分析師報告的主題。Kepler Capital Markets 在 3 月 13 日（星期四）的研究報告中將諾和諾德公司的股票評級從 “持有” 上調至 “買入”。StockNews.com 在週二的研究報告中將諾和諾德公司的股票評級從 “強力買入” 下調至 “買入”。Stifel Nicolaus 在 3 月 3 日（星期一）的研究報告中將諾和諾德公司的股票評級從 “買入” 下調至 “持有”。BMO Capital Markets 在週四的研究報告中重申了 “市場表現” 評級，並對諾和諾德公司的股票設定了 64.00 美元的目標價（之前為 105.00 美元）。最後，瑞銀集團在 1 月 8 日（星期三）的報告中將諾和諾德公司的評級從 “賣出” 上調至 “買入”。一位投資分析師對該股票給予了 “賣出” 評級，四位給予了 “持有” 評級，六位給予了 “買入” 評級。根據 MarketBeat.com，諾和諾德公司目前的平均評級為 “持有”，平均目標價為 135.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on NVO</strong></p>
<div class="lb-trans"><p><strong>查看我們對 NVO 的最新分析</strong></p>
</div><h2>Novo Nordisk A/S Company Profile</h2>
<div class="lb-trans"><h2>諾和諾德公司公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>諾和諾德公司及其子公司從事藥品的研究與開發、生產和分銷業務，覆蓋歐洲、中東、非洲、中國大陸、香港、台灣、北美及國際市場。它分為兩個部門，分別是糖尿病與肥胖護理和罕見疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Novo Nordisk A/S</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally</li>
<li>How to Invest in the Best Canadian Stocks</li>
<li>Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過諾和諾德公司</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>關税豁免為台灣半導體的反彈鋪平道路</li>
<li>如何投資最佳的加拿大股票</li>
<li>緩解關税：三隻股票從美元走弱中獲益</li>
<li>稀釋每股收益（Diluted EPS）是什麼？</li>
<li>博通與蘋果的關係：人工智能機會與關税風險的交匯</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在諾和諾德公司嗎？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮諾和諾德公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而諾和諾德公司並不在名單上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然諾和諾德公司目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

景順投資管理有限公司減少了其在諾和諾德公司（NYSE:NVO）的股票持倉